Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial(aEuro)

N Zdenkowski; JF Forbes; FM Boyle; G Kannourakis; PG Gill; E Bayliss; C Saunders; S Della-Fiorentina; N Kling; I Campbell; GB Mann; AS Coates; V Gebski; L Davies; R Thornton; L Reaby; J Cuzick; M Green

Journal article

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial(aEuro)

N Zdenkowski, JF Forbes, FM Boyle, G Kannourakis, PG Gill, E Bayliss, C Saunders, S Della-Fiorentina, N Kling, I Campbell, GB Mann, AS Coates, V Gebski, L Davies, R Thornton, L Reaby, J Cuzick, M Green

Annals of Oncology | OXFORD UNIV PRESS | Published : 2016

DOI: 10.1093/annonc/mdw055

University of Melbourne Researchers

Michael Green Author

Bruce Mann Author Surgery - Royal Melbourne Hospital

Grants

Awarded by Australian National Health and Medical Research Council

Awarded by Cancer Research UK

Funding Acknowledgements

The work was supported by the Australian National Health and Medical Research Council (Grant ID 510787) and the Breast Cancer Institute of Australia. Novartis Pharmaceuticals Australia Pty Ltd supported the trial and commented on findings but played no part in the data analysis or interpretation. The Breast Cancer Research Foundation part-funded biospecimen handling (no grant number applicable).